reason report
bottom line follow recent publish hospit
administr survey link publish individu one-pag
compani preview cardio ew
nvcn large-cap diversifi diabetes/
thought follow one-pag individu compani preview follow
includ detail view around expect setup head
print well views/stanc stock
see highest potenti beat rais ahead
even potenti elev expect likelihood share
upsid print
compani high convict potenti
quarterli beat either top bottom-lin may rais
guidanc enough and/or issu ahead consensu
guidanc could limit share upsid includ
compani see risk print includ ew --
believ could fail deliv elev investor expect
 tavr -- believ bracket consensu
sale ep guidanc could disappoint quarterli
compani coverag univers either expect
larg in-lin print reason expect like caus
stock trade sideway and/or stock reaction larg
predic clinic updat includ nvcn
detail includ insid
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
leerink partner factset
quarter expect deliv solid quarter out-performance driven
continu impella adopt momentum cardiogen shock high-risk pci
sale estim y/i slightli street y/i
regardless expect deliv sale growth closer -- line top-lin growth
deliv ahead consensu sens beat driven primarili
believ continu acceler within cardiogen shock increas center
particip cardiogen shock initi nationwid upsid may seem modest
expect stock reaction larg predic guidanc issu post-
earn confer call think like rang bracket estim
y/i consensu y/i
stanc believ well track exceed long-term vision revenu
compani need deliv low-to-mid compound-annual-growth-rate reach
sale cardiogen shock momentum seem acceler initi spread
nationwid top alreadi steadi uplift high risk pci adopt
increas confid abmd abil deliv consist sale upsid admittedli street
expect increasingli elev rich valuat place pressur compani
deliv strong beat rais quarter given abmd monopoli posit market
would recommend buy weak stock under-perform print
quarter expect well posit deliv top bottom-lin beat
quarter importantli exceed believ organ sale growth expect
investor sale estim fall consensu also
reflect mid-single-digit organ sale growth ex fx see sale upsid potenti key
area recent launch mri safe high-pow devic continu drive share
gain strength on-going freestyl libr roll-out think could deliv
upward sale base recent script trend stronger execut
ou pediatr nutrit specif china vs estim low-single-digit organ
sale growth easiest y/i compar sale upsid also expect deliv ep
out-performance come ahead manag ep guidanc rang despit
sale ep out-performance expect manag reiter full-year sale guidanc
organ growth ep given still earli year
stanc expect guidanc call organ top-lin growth
double-digit ep growth -- achiev remain sidelin pend clariti
sustain impact new product launch given view solid execut new product
launch key upsid aler integr on-going nutrit
turnaround underway acknowledg execut risk stori despit
risk think well-posit least deliv near-term sale growth ep
resultsactuallp estimate y/i consensusvariancetot good gross gener administr develop ep metricstot impella custom patient treat per breakdownu impella impella impella non-impella compani report factset consensu visibl alpha consensu leerink partner resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop ep region total segment total cardiovascular establish pharmaceut compani report leerink partner estim factset visibl inc outperform price
quarter expect least come line revenu estim
y/i view manag reset bar low enough given mix
busi compani well-posit deliv consist out-performance throughout
year manag guid sale growth think solid execut
achiev least sale growth high-single-digit growth open ablat low-double-
digit growth minim invas strong double-digit growth atriclip estim
sale y/i street y/i middl
guidanc rang y/i leav room upsid view
dont howev expect manag rais guidanc given still earli year investor also
focu continu progress converg enrol patient enrol late februari
manag guid enrol complet
stanc bar reset believ expect suffici low posit
consist beat rais near-to-medium term ultim still confid atrc
sustain double-digit sale growth outlook clear path profit driven growth
potenti open ablat strong double-digit growth atriclip next year longer term
believ mi minim invas surgeri drive sustain double-digit growth
inclin think multibillion-dollar market opportun underappreci street minim
valu assign current valuat level
quarter expect deliv anoth solid beat rais though larg expect
street stock move come guidanc rais beat commentari around
sustain growth driver thought capit deploy investor seek clariti
possibility/likelihood posit bia point inclin think share
trade print would buyer ahead quarter estim ep vs
consensu recal guidanc call organ top-lin growth ep
came somewhat consensu time issu wed expect exceed
guidanc rang partial help stronger-than-usu flu season rais guidanc
reflect beat least near term upcom analyst day may like
next catalyst stock anticip manag provid overarch strategi framework
newly-reclassifi gbu global busi outlin potenti driver upsid vs prior
guidanc rais long-term guidanc
stanc view growth acceler stori underli sale growth momentum across
busi larg underappreci street bax current long-term vision expect
sale compound-annual-growth-rate time-frame oper margin vs us consensu
sale compound-annual-growth-rate period nearli oper margin believ manag long-
term sale growth guidanc move least mid-single-digit level still achiev
like beatabl view given confid bax renal busi least return broader market
growth alon repres sale gener inject biosurgeri
reacceler line high-single-digit mid-to-high singl digit growth respect driven
recent acquisit clari two compound posit product cycl
research develop expens
sg revenu
 revenu
good sold
compani report factset consensu visibl alpha consensu leerink partner estim
resultsactuallp estimate y/i growthconsensusvariancetot product gener administr develop incom ep region breakdownopen-heart ablat ablat tool compani report factset consensu visibl alpha consensu leerink partner boston scientif corpor outperform price
quarter expect deliv sale upsid vs us street
y/i respect sale estim assum organ growth
think like approach given continu strong momentum medsurg
deliv double-digit growth ten consecut quarter like upsid structur heart
particularli watchman acur europ market share gain back
on-going mri-saf high power launch expect allow penni two sale upsid
fall bottom line bring ep manag guidanc rang despit
expect sale ep upsid quarter dont anticip guidanc rais
current organ sale growth ep given earli year
could limit upsid share print
stanc believ repres one attract top- bottom-lin growth stori
large-cap med-tech deep product pipeline/portfolio signific posit oper leverag
potenti despit lotu setback continu believ one posit
product cycl large-cap cardiolog posit compani well deliv sustain high-
single-digit sale growth forese futur expect least portion top-lin growth
acceler fall bottom-lin like exceed goal oper margin
deliv mid-to-high teen ep growth
quarter expect csii revenu come in-lin us consensu
respect repres high-single-digit sale growth
modest acceler suffer salesforc product issu
recently-ad clinic rep ramp now-separ coronari salesforc
start contribut meaning believ modest growth acceler achiev
think beat unlik given new rhonda robb join month
quarter salesforc product issu sometim take time resolv expect
manag reiter recently-low sale guidanc
impli y/i growth back half year see limit downsid risk
stanc continu believ repres sustain double-digit growth stori
improv execut given believ compani signific competit advantag
calcifi below-the-kne lesion within peripher well grow market-
lead posit highli under-penetrated coronari market execut improv
product recently-ad rep ramp believ compani well-posit growth
acceler us recent pullback repres buy opportun investor
recent manag chang busi develop activ sale forc restructur
posit compani improv execut acceler growth go forward
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop incom ep region total product total rhythm compani report factset consensu visibl alpha consensu leerink partner resultsactuallp estimate y/i growthconsensusvariancetot product gener administr develop incom ep metricspad new new pad devic cad devic breakdownpad devic devic product compani report factset consensu visibl alpha consensu leerink partner dexcom inc outperform price
quarter expect deliv strong beat estim y/i
consensu think out-performance larg driven still-strong adopt
momentum commerci patient said acknowledg strong beat larg expect investor
also think one quarter year possibl new cfo quentin blackford leav
sale guidanc unchang despit like strong beat earlier-than-expect
approv best think blackford rais beat could limit upsid share given
stock recent run beyond financi outlook believ main focu call launch
just-approv updat verili timelin might acceler base move
stanc share trough level sinc septemb still see
share upsid street number investor expect remain low recent cgm survey
clearli suggest sustain double-digit growth despit libr launch medacorp respond
expect dxcm instal base grow nearli well estim
assum basic flat commerci new patient add ultim believ current guidanc
 mid-point conserv leav room meaning upsid consensu
estim need move much higher
quarter expect ew deliv modest beat quarter vs estim
y/i consensu tavr busi estim y/i
sequenti vs street y/i think there margin upsid
estim base trend suggest recent tavr survey intern project tavr
revenu y/i vs street ew guid sale high
end impli y/i growth ep compar
sales/ep estim consensu believ manag like
maintain guidanc unless see meaning tavr out-performance current
stanc continu believ ew retain market-lead posit massiv market
opportun near-to-medium term ramp could progress slowli saw high
risk/inoper remain cautiou near-to-medium term intermedi risk ramp rel
believ increasingli elev street expect still premium valuat level sens ew
continu deliv strong beat rais quarter order drive share upsid
recent note medacorp tavr survey
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop continu ep region domest product thv corevalv thv thv transcathet heart surgic heart valv critic compani report leerink partner estim factset visibl resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop ep region total breakdown total sensor transmitt compani report factset consensu visibl alpha consensu leerink partner inc outperform price
quarter expect deliv anoth strong top-lin beat rel us
street y/i expect predic compani consist
track record record sale beat everi quarter sinc first public quarter march
recent detail believ rel benign manag secur breach
portion rental patient compani also cite strong result note
manag provid updat guidanc result releas base recent
trend inclin believ out-performance larg driven compani busi
specif domest modest out-performance possibl direct cash sale busi
recently-ad rep new cleveland facil ramp product like sale out-performance
expect beat margin ep though bottom-lin beat like modest
natur compani reinvest upsid sale market initi also post-
earn confer call wed expect manag address timelin unveil next-gen
product possibility/tim enter new geographi specif china
stanc view best-in-class portable-oxygen-concentr poc
market uniqu direct-to-consum busi model posit compani sustain
double-digit growth trajectori longer term outpac growth oxygen therapi market
believ well-posit deliv beat rais quarter forese futur driven
focu shift reimbursement-pressur rental toward dtc busi model acceler
quarter expect kick med-tech earn season like set investor
expect quarter relat procedur volum trend overal base
hospit administr survey look basic stabl reflect expect modest seasonally-driven
step vs expect deliv sale ep upsid estim
consensu given rel healthi util backdrop reflect survey
potenti boost stronger flu season pharma drive lion share
out-performance vs admittedli too-low estim like continu adopt ramp new drug
like tremfya darzalex well easier y/i compar key legaci drug like zytiga
invokana given move part -- includ potenti gener competit
zytiga octob -- think manag reiter current guidanc call organ top-
line growth ex fx acquisit divestitur rang y/i see
potenti upsid consensu ep estim prior cost-sav
initi reach peak save drive meaning margin expans vs basic stabl
margin street model wed expect compani continu divest slower-
growth lower-margin busi much like on-going divestitur diabet devic busi
stanc believ jnj diversifi busi model allow compani manag
near-term headwind specif one busi pharma patent cliff on-going
turnaround consum reacceler medic devic expect return market
growth above-market pharma growth profil well-posit ultim return
sustain above-market sale growth deliv even faster ep growth
resultsactuallp estimate y/i growthconsensusvariancenet gener administr develop ep region total product total medic devic pharmaceut consum compani report first order analyt consensu leerink partner resultsactuallp estimate y/i growthconsensusvariancetot develop market administr incom ep domest domest direct sale compani report factset consensu leerink partner plc market perform price
quarter expect basic come slightli ahead us street
sale oper line street ep
see downsid risk street oper margin importantli manag
issu guidanc earn call believ like bracket current estim
street number current estim sale -- impli organ
growth ex fx divestitur report growth rate y/i ep
organ report compar consensu
expect manag guid organ top-lin growth mid-single-digit growth rang
high-single-digit ep growth reflect headwind coupl hundr basi point
item oper line lower interest incom anniversari account chang
stock-bas compens transit servic divest cardin
valuat in-lin quarter could enough one mdt biggest issu around
drive consist posit oper leverag expect quarter
stanc remain sidelin pend clariti fundament competit
product launch on-going competit pressur manag confid
mdt abil drive sustain mid-single-digit top-lin growth primarili driven new therapi
innov emerg market given execut risk remain cautiou addit
see increment margin expans tough come given top-lin dynam
quarter expect nvcn focu tiara clinic progress financi health
compani cash bank least time legal overhang
remov still compani cash posit sustain develop next quarter
point manag hope posit tiara closer market nvcn report
total number tiara implant reach march novemb believ
manag provid updat clinic trial progress tiara like acceler enrol
provid clariti potenti time tiara trial complet current target
end nvcn exit cash hand receiv increment
exercis seri warrant april suffici fund day-to-day oper
next month view
stanc view nvcn front runner commerci tmvr transcatheth mitral
valv replac devic multi-billion market possibl peak much
litig settl compani need provid anoth fundrais plan
remov financi overhang investor clariti nvcn continu oper
believ nvcn share move meaning higher appropri reflect believ
lead posit massiv long-term market opportun
resultsactuallp estimate y/i growthconsensusvariancenet good gener administr develop ep region total product cardiac vascular group invas therapi group mitg therapi group compani report factset consensu visibl alpha consensu leerink partner resultsactuallp estimate y/i growthtot good gross gener administr develop ep compani report leerink partner corp outperform price
quarter expect beat revenu estim y/i
consensu like come driven larg better-than-expect
 sale current model market growth procedur volum
perspect well nearli growth saw half point share shift
increment point market growth would add
sale everi increment half share point would add nvro sale upsid
potenti particularli evid look rep add ad
rep repres highest net rep add quarter sinc launch senza
rep product continu ramp throughout year cover territori see
meaning upsid potenti current sale guidanc y/i
mid-point vs estim consensu think strong print could
prompt manag rais full year sale guidanc least reflect beat
stanc confid nvro sustain double-digit sale growth trajectori
outpac project double-digit growth rate broader spinal cord simul market
compani gain share also expand market meaning
previous untreat predomin back pain patient popul near-term continu
view much execut stori upsid larg conting ramp rep
product increas salesforc coverag new vice-president sale appoint decemb
quarter expect deliv anoth solid top-lin beat rel estim
y/i consensu upper half guidanc rang
think like see growth come low rang
potenti put sale number closer driven out-performance core
omnipod busi despit normal season weak
quarter omnipod see upsid mid-teen sale growth estim vs
new patient add continu ramp intern see acceler purchas
possibl current distribut partner ypsome prior podd mid-year transit direct
sale margin expect deliv least bp gross margin expans
bp possibl strong sale beat importantli expect
rais sale guidanc current y/i even
beat given recent coverag announc
stanc top pick smid-cap med-tech view one cleanest
execut stori within smid-cap coverag univers compani pois continu
deliv consist beat rais quarter top-lin sign slow momentum
believ ramp adopt still larg under-penetrated pump market
primari market grower given highli differenti wearabl footprint drive sustain
double-digit growth forese futur addit model ebitda profit
ebit profit driven on-going gross margin expans
resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop ep metricsend us breakdowndomest compani report factset consensu visibl alpha consensu leerink partner resultsactuallp estimate y/i growthconsensusvariancetot good gross gener administr develop incom cont ep overviewtot us omnipod omnipod deliveri revenu compani report factset consensu first order analyt leerink partner hold inc outperform price
quarter expect deliv anoth basic in-lin quarter driven
on-going eversens adopt momentum europ key share perform
anecdot commentari around on-going germani launch increment launch
commentari eu countri importantli updat approv
timelin overwhelmingli posit fda panel believ fda approv
matter sens point product launch could shift
regardless time look manag provid color
commerci plan addit updat investor need addit
fundrais given recent convert atm
stanc believ verg dramat sale inflect point
expect launch eversens implant cgm continu glucos
monitor believ nearli total address market alon
confid born continu posit earli feedback on-going
european launch expand germani itali seem ramp well
appear strong recept patient physician could/should serv
proxi ultim adopt
quarter expect deliv meaning upsid current
estim y/i street driven ramp maci
adopt trend compani continu train surgeon improv util
new exist account acceler biopsi growth key lead indic
manag longer provid biopsi growth metric last quarter
saw growth model current assum new
surgeon train quarter vs train alon util fall
procedur per surgeon vs estim us leav
plenti room upsid given view current guidanc
 y/i conserv easili beatabl inclin think
manag like rais guidanc sale exceed
rang impli manag guidanc expect deliv
gross margin compani drive leverag ramp volum
stanc believ sustain top-lin grower next
year driven ramp adopt highli under-penetrated articular cartilag
repair market sever burn market peg combin maci epicel
address market opportun hold virtual monopoli
maci actual monopoli epicel addit believ gross margin
continu improv case volum continu ramp drive meaning oper
leverag achiev ebit net incom profit
resultsactuallp estimate y/i growthtot gross gener administr develop ep compani report leerink partner resultsactuallp estimate y/i growthconsensusvariancetot develop gener administr incom ep breakdowncarticel maci compani report factset consensu leerink partner medic devic
rate share outperform price target believ abiom
manufactur impella impella cp percutan ventricular assist devic
pvad well-posit deliv sustain strong double-digit sale growth near-
to-midterm time-frame project sale compound-annual-growth-rate
compani drive increas penetr prophylact high-risk percutan
coronari intervent pci cardiogen shock patient popul estim
patient treat abiom impella impella cp
pci perform annual base medacorp physician convers
anywher pci could consid high-risk would benefit
impella anoth pci cardiogen shock patient
compani benefit new product higher flow impella cp receiv pma approv
 april indic cardiogen shock new geographi
notabl japan receiv approv octob launch impella
compani continu add new center
center total ad center per quarter
us biggest barrier impella adopt awar impella
pma-approv protect pci impella devic includ higher flow impella cp
approv cardiogen shock aggress market train
hospit heart team util broad clinic dataset train capabl impella
six clinic guidelin drive awar help guid clinic
practic eas patient select
even adopt inflect upon protect pci pma approv late believ
impella adopt pois ramp given
highli under-penetrated market opportun within protect pci cardiogen shock
impella today penetr
concert effort among physician rais awar around treat grow
number complex high risk patient pci procedur volum patient grow
mid-single-digit rang base estim
pma approv protect pci cardiogen shock allow
aggress market impella use broad clinic dataset support safeti efficaci cost-
effect well train clinician nurs
indic geograph expans on-going launch impella rp
patient opportun on-going launch japan current
patient balloon pump patient extracorpor membran oxygen
ecmo repres low-hang fruit impella view
oper margin expans stori believ abiom drive on-going posit oper
leverag primarili within sg ultim push oper margin nearli
next month believ share
move higher current level compani continu deliv consist quarterli sale
beat push oper margin higher
next month believ share trade appli ev/
sale multipl estim assum current multipl
sale sustain believ sustain strong double-digit growth profil
profit warrant premium repres uniqu asset increasingli volatil market
strong track record out-performance clear pathway earn upsid strong
balanc sheet cash end quarter debt
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
rate share market perform price target abbott like
path top-lin growth acceler compani like reinvest
busi absorb acquisit includ alr stj deal
potenti bolster compani sale ep growth outlook becom
formid player med-tech diagnost even broader offer
near term uncertainti around integr stj alr like continu
reflect market sentiment beyond believ margin expans continu
remain key piec abbott long-term invest thesi abbott also attract investor
look safer defens stock healthi dividend yield current
increasingli volatil market help sustain current multipl abbott
succeed drive meaning margin expans nutrit busi margin
mid-teen level post-split still go increas cost effici
suppli chain manufactur abbott pipelin also number smaller
increment new product launch expect next year beyond
pend acquisit xienc stori larg play estim basic
stabl drug elut stent market share next year view abbott like
less acquisit immedi term two larg acquisit underway alreadi
estim reflect uncertainti around integr larg acquisit stj
expect share trade assum multipl basic
unchang ep estim assum share sustain current
price-to-earnings multipl ep estim clearli pois sale growth
acceler next year believ current valuat alreadi reflect potenti
execut risk around new product launch -- heavili depend notabl
freestyl libr mri-saf high power devic -- see opportun potenti
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
rate share outperform price target
believ well-posit sustain double-digit top-lin growth least next
year compani core open ablat busi -- make sale
-- well-posit deliv sustain mid-single-digit growth forese futur
penetr ramp beyond guidelin chang acceler growth
continu advanc mi minim invas ablat pipelin could ultim open
multibillion-dollar atrial fibril af ablat market opportun address
atrial fibril patient
ceo carrel appear commit compani current long-term growth strategi
penetr concomit open heart surgic ablat market expand mi surgic
ablat drive atriclip sale cross-sel expand intern
near term manag work ensur limited-to-no sale forc disrupt compani
continu focu penetr global concomit surgic ablat market --
less penetr today compani success advanc clinic trial
initi converg frost deep progress
next month believ share trade valuat appli
ev/sal multipl revenu estim assum basic stabl
multipl current level estim compani get back
track deliv consist out-performance street estim move higher current level
believ share deserv trade line broader small-cap med-tech
univers averag includ nxtm
believ compani continu deliv given stabl mid-to- high-teen sale
growth outlook long-term mi come on-line potenti meaning sale oper
synergi estech ncontact acquisit close increasingli clear
pathway profit beyond turn ebitda posit base
risk includ failur success execut surgeon train new af indic
adopt concomit surgic ablat clinic trial delay failur receiv
clearanc next gen atriclip system ou regulatori delay ncontact
rate share outperform price target ten consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free
cash flow target vs expect
last may analyst day potenti upsid free
cash flow view increas financi flexibl invest busi
drive even faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recently-upd long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
deliv oper margin margin improv
clearli track ahead schedul believ ultim potenti oper margin like
well line compar large-cap med-tech compani see room
upsid margin ramp believ major upsid alreadi price share
level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement ev/
ev/ebitda analys ev/ebitda perspect valuat right line
group includ ew
failur execut margin expans initi new product launch delay possibl
acquisit either dilut perceiv further baxter growth goal could
pressur stock
rate share outperform price target turnaround stori
well underway new manag deliv solid execut near- long-
term sale ep growth target build foundat sustain top-tier sale growth
within large-cap med-tech univers given compani recent consist deliv
ep line better expect upcom slew new product launch
increasingli confid well track achiev long-term goal laid
june analyst meet includ achiev organ sale growth
compound-annual-growth-rate -- faster broader med-tech market mid-single-digit rang
deliv gross margin achiev oper
margin togeth solidli posit deliv double-digit ep growth
next year view even growth guidanc slightli
organ sale growth deliv organ sale growth alreadi
well track achiev long-term sale growth goal manag indic confid
sustain recent pipelin commerci execut continu roll-out
sever key new product launch meaning contributor top
bottom line includ limit watchman left atrial appendag closur devic
continu roll-out exceed expect mri-saf high power devic
launch symeti close pipelin product coupl
recent launch acquir product includ am men
prostat portfolio posit increment sale growth acceler
leav potenti upsid current project sale compound-annual-growth-rate
without risk notabl outstand litig issu
mesh product ir transfer price next month believ share
well-posit out-performance compani continu deliv consist quarter
solid execut potenti out-performance also hit key new product mileston
remov remain litig overhang
next month believ share trade deriv appli
price-to-earnings multipl cash ep estim basic line
large-cap med-tech group broadli top-tier sale
growth profil mid-to-high singl digit rang near-term ep growth profil
line group think line multipl fair compani continu deliv
solid execut consist meet-or-beat quarter also ramp key new product
move past litig issu see opportun multipl expans ahead
risk includ lack meaning recoveri med-tech market broadli major boston
scientif market drug-elut stent de cardio rhythm monitor
specif failur success execut key new product launch major litig
loss potenti product recal particularli within inabl suffici reduc
cost drive oper margin expans
rate inc share outperform
month price target sever solid quarter row stabl improv growth
new ceo place believ compani reach fundament inflect point
sever quarter under-perform due sale forc disrupt poor execut
alway view well-posit market leader peripher atherectomi market
grow sustain high-single-digit rang coronari atherectomi market grow
even faster given competit advantag calcifi lesion knee heavili
under-penetrated market within space previou cautiou view share
larg predic lack execut august announc interim ceo
scott ward take perman continu transit make us increasingli
confid recent sale forc stabil thu improv growth trajectori sustain
near-to-medium term
longer term believ atherectomi market may posit acceler growth
advent drug coat balloon dcb particularli indic secur
knee within next year investor fear dcb competit
atherectomi devic medacorp physician check strongli suggest fact
complementari physician use atherectomi debulk prep lesion particularli
heavili calcifi sweet spot liberti still on-going
remain one compani develop substanti dataset support atherectomi
adopt highli under-penetrated market particularli sickest critic limb ischemia
patient larg untreat current lastli coronari gain like
continu aggress gain share also grow market believ reach
penetr total pci low-single-digit today
increas focu among intervent cardiologist treat complex higher risk patient
atherectomi like becom increasingli import
beyond top line csii effort control cost announc restructur march
includ reduct workforc could push compani profit faster
previous expect believ turn sustain net incom profit
current fiscal year pathway profit enabl attract broader
investor base attract new money name continu support share
price target appli ev/sal multipl estim
reflect basic stabl sale multipl sale estim
discount small-cap coverag univers nxtm
given view underli fundament much intact
believ share pois move meaning higher manag drive back toward
market share potenti product recal failur dcb drive atherectomi adopt
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea --
essenti cgm-augment insulin pump system automat accur dose
patient new patient adopt momentum -- set launch -- like
sustain sale growth near medium term despit competit headwind continu
product evolut includ possibl much less-costli type product conjunct
googl partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share
current trade sale estim basic line
compar small-cap med-tech compani still
reflect notabl multipl contract premium level trade
previous investor visibl achiev top-tier growth
timelin lower-cost verili product exist competit overhang share
lift view acknowledg take play
back half stori ultim believ share warrant least
modest premium small-cap med-tech stock univers given massiv
highli under-penetrated total address market per estim consist
upsid potenti top-tier growth outlook longer term
risk includ failur success secur fda approv time manner
failur continu evolv sensor technolog includ verili product type patient
toward sensor-integr pump potenti price pressur increas competit
potenti product recal reimburs issu
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient may slower
saw inoper high risk given linger question around tavr
durabl longer term need seemingli intens market develop effort
drive referr particularli younger less sick portion intermedi risk patient
popul potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed line ew
guidanc new indic come on-line low risk eventu asymptomat
near-to-medium term ew still beat rais stori base earli read
intermedi risk adopt ramp think beat next month may
smaller tougher come last two year particularli light
competit launch addit steadier intermedi risk ramp vs step function chang
growth street seem expect share current trade earn
becom increasingli difficult argu meaning multipl expans leav us
upsid current level base estim
price target appli price-to-earnings multipl ep estim
pt assum ew maintain current multipl ep also think ew
market-lead posit highli under-penetrated total address market justifi
compani premium valuat rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
rate share outperform op price target view
differenti technolog competitor larg under-penetr fast-grow long-
term oxygen therapi ltot market manufactur market portabl oxygen
concentr poc that gener view best-in-class base efficaci size allow
superior portabl patient mobil compani also implement uniqu direct-to-
consumer- dtc sale strategi despit well-known reimburs headwind protect
profit margin still allow higher invest versu competitor
time-frame project deliv sale compound-annual-growth-rate even
absorb increment reimburs cut
poc therapi class expand within ltot given favor demograph broaden
awar earlier diagnos underli condit copd longer life
expect oxygen therapi medacorp physician survey check suggest
poc could move much ltot mid-single-digit penetr today base
appropri patient
drive continu market share gain within poc increas awar
barrier adopt poc broadli compani inogen one specif exist
includ lack awar poc inogen one potenti higher
up-front cost patient versu tradit oxygen therapi awar continu grow
compani continu invest build sale forc dtc market effort
word mouth take hold cost frequent cite issu medacorp
physician survey spoken continu technolog improv higher
patient invest therapi decis could help mitig barrier us repres
compel invest opportun med-tech investor given high-sal growth
profit profil despit alreadi well-known reimburs headwind next
month believ share could move higher current level success execut
quarter potenti deliv upsid could prove conserv estim
price target appli ev/sal multipl
sale estim assum stabl multipl current share trade
today estim ev/sal multipl small-cap
med-tech univers nxtm broadli
believ repres uniqu asset within small-cap med-tech top-tier growth profil
profit togeth warrant premium
risk share includ account issu possibl greater reimburs cut
current model loss increment competit bid contract exclud
compani access new patient potenti competitor replic implement
compani dtc strategi inabl build awar drive increas penetr
poc oxygen therapi market
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson seem also
becom offens compani success gener posit momentum
reacceler growth suffer sever year below-industri growth
johnson johnson weather slow med-tech util trend ramp price pressur
major pharma patent expir actelion johnson johnson seem pois
drive sustain organ mid-single-digit top-lin growth even better high-single-digit bottom-
line growth long-term help success recent new pharma product launch zytiga
imbruvica xarelto invokana continu innovation/in-licens re-launch full
over-the-counter product portfolio basic stabl seemingli improv med-tech util
trend broadli depuy/synth trend specif compani work
integr issu dividend yield strong free cash flow gener believ
share repres attract total return vehicl investor
next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
rang rel ep estim basic line large-cap diversifi
comp group price target assum
share sustain multipl compani manag top-lin headwind
continu manag cost benefit actelion -- posit sustain
ep out-performance view total return capabl attract increasingli
volatil stock market environ like attract fund riskier area
risk includ failur success integr actelion amo synth potenti futur
acquisit failur resolv outstand consum consent decre success
re-launch product product recal failur advanc late-stag pipelin
success launch new product protract recoveri procedur volum trend
lack real macroeconom recoveri
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
compani goal reach cost synergi remain aggress despit
made meaning progress toward goal
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
share current trade ep modestli high-
teen multipl rang broader large-cap med-tech univers though
believ could eventu return path consist mid-single-digit top-lin
growth time less certain see limit multipl expans
mid-single-digit growth trajectori larg predic recent upcom new product
launch sustain trend without risk price target
appli basic stabl multipl ep estim
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
rate nvcn share outperform price target though still earli
develop believ neovasc verg tap dramat larg
potenti high growth transcathet mitral valv replac tmvr market tiara
technolog neovasc tiara current forefront still nascent develop
market total number implant reach patient either feasibl
compassion use mitral regurgit mr preval aortic stenosi
tmvr clearli repres massiv virtual unpenetr market opportun peg
global tmvr market opportun assum tmvr initi target function mr patient
high risk surgeri almost tripl current transcathet aortic valv
replac tavr market estim use tavr proxi clear demand
less invas transcathet therapi high valvular diseas patient mr particularli
sever mr repres highli underserv patient popul poor surgic outcom
drive surgic penetr rate less total market tiara clearli
without risk given earli stage develop medacorp physician check suggest
tiara repres highli viabl solut given anatom d-shape leaflet independ
anchor mechan next month tiara pois hit number clinic
mileston investor abl gaug develop progress upon
nvcn share like react includ
complet enrol on-going feasibl studi ou
studi least patient alreadi enrol
feasibl studi data potenti late-break spring medic meet measur
procedur success outcom mace follow-
initi ce mark trial late upon feasibl studi complet ce mark approv
possibl earli
 pivot studi upon complet on-going feasibl studi
believ neovasc deliv compound annual top-lin growth
see potenti upsid alreadi top-tier sale growth profil driven
rapid aggress tmvr market develop europ
model assum fairli modest penetr rate address market sever year
launch european penetr penetr
potenti competit setback current assum neovasc edward secur
eu approv time fast follow howev
high probabl one competitor could face clinic setback fail reach
market
potenti faster ww tmvr market growth potenti market expans either
degen mr and/or moder risk patient popul model current assum
tmvr address function patient high risk surgeri
next month believ nvcn share trade arriv price target
use discount cash flow dcf analysi take averag valuat base rang
royalti rate dcf use discount rate probability-
weight believ dcf appropri consid neovasc expect sale inflect
point tiara potenti ce mark approv earli potenti approv
launch acknowledg small-cap med-tech compani valu base
compar compani ev/sal multipl believ dcf best captur total address
market opportun neovasc tiara tmvr market estim potenti
risk neovasc rate valuat includ possibl tiara and/or reduc
approv us and/or europ commerci ramp tiara and/or reduc fail
meet expect challeng fda approv pathway tiara and/or reduc
fairli robust competit landscap mr replac pipelin on-going trademark
potenti patent litig potenti reimburs risk failur obtain suffici
reimburs tiara and/or reduc secur approv
rate share outperform price target believ
well-posit drive sustain growth current global spinal cord
stimul market senza therapi system treat chronic pain also view
differenti senza high frequenc therapi like market growth stimul
adopt predomin back pain patient larg untreat previous due lack efficaci
like acceler senza given proven efficaci patient popul ultim
see faster-grow market increment market growth larg
accru
believ deliv compound annual top-lin growth
see potenti upsid alreadi top-tier sale growth profil driven
rapid aggress market share gain back fda approv
senza hf -- label includ pivot trial data claim superior vs tradit
dramat eu market share gain superior label place
senza-rct clinic data wide dispers public peer-review
medic journal releas data nan annual meet decemb
potenti faster market growth aggress adopt therapi
increas sale forc ramp penetr key account beyond
next month believ share trade appli
ev/sal multipl sale estim assum stabl multipl vs current
ev/sal level multipl larg line small-cap med-tech
risk share includ difficulti shift physician adopt away current
cut potenti high frequenc competit anoth major player could impact
long-term market share and/or forc enforc intellectu properti ip right
like time-consum expens effort increment reimburs cut may
pressur price longer term
rate share outperform price target next
year continu focu drive strong referr momentum increas sale
forc product greater awar deliv believ around
top-lin compound-annual-growth-rate time-frame ex neighborhood diabet underw
manag transit almost two year ago busi stabilized-to-
acceler believ long-term market opportun type patient unchang
new manag expand market opportun type patient broader
drug deliveri solid execut continu reinvest sale forc appear
pois drive sustain re-acceler new patient add beyond diabet
compani meaning opportun platform drug deliveri technolog non-insulin
sale underway expect ramp least total sale next
year base estim
continu rate share op price target -- appli ev/revenu
multipl now-high sale estim share current trade
sale estim expect multipl hold current level given
believ sustain double-digit growth next year path
profit key issu smid-cap med-tech investor believ share deserv
trade least high end ev/sal multipl smid-cap med-tech
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
rate share outperform price target believ senseon
verg dramat sale inflect point european launch eversens
day implant continu glucos monitor cgm progress even importantli
expect launch believ nearli total address
market alon still today global cgm market still much
earli stage adopt increas awar improv reimburs
continu technolog evolut longer-wear implant sensor senseon
eversens play key role like continu drive rapid growth via expand patient
popul eventu aggress penetr beyond type much-
larger multi-million type patient popul view eversens appeal broad patient
popul encompass type current declin cgm option due
high burden therapi patient also type reason us posit
compani dramat top-lin growth next year clear path profit
modest penetr type margin penetr insulin-depend
type believ senseon deliv compound-annual-growth-rate time-frame
ramp sale see potenti upsid
estim driven
solid launch execut supplement potenti faster sale forc add
success pipelin execut expect approv sensor
faster market entri sensor would competit differenti
beyond solid execut drive sale inflect expect benefit
number posit catalyst next month includ
anticip eversens approv possibl launch
continu roll-out eversens xl rest europ
next month believ share trade price target appli
ev/sal multipl sale estim current share trade
estim slightli small-cap med-tech coverag univers
current trade sale estim believ
premium warrant
near-to-medium term sale growth profil top-tier hyper-growth small-
project sale growth well sale growth compound-annual-growth-rate project
time-frame
share trade sale estim slightli small-cap
med-tech coverag univers trade sale
expect modest contribut launch
potenti strong us ramp
risk share includ difficulti shift physician adopt away current
tradit cgm therapi increas competit counter-detail failur build
success sale forc train physician drive adopt failur advanc
pipelin includ sensor expand indic pediatr
initi coverag share outperform rate price
target believ maintain virtual monopoli highli under-penetrated articular
cartilag repair market could ultim see open-end growth long-term recently-
launch maci product repair larg cm
cartilag defect seen sale
growth acceler mid-single-digit
third-gener product launch broadli one-of-it kind amount
support clinic data includ summit trial demonstr superior vs standard
care microfractur year carticel use first-gener product
maci procedur base eas use faster rehabilit time increas
appeal physician orthoped surgeon special sport medicin patient
physician train util maci continu ramp believ deliv
least sale growth next year mid-teen growth sustain go-forward
basi high end compar small-cap med-tech compani coverag univers
see signific opportun upsid alreadi above-street estim driven
even higher number orthoped surgeon util maci total
orthoped surgeon identifi sport medicin specialist model current assum
surgeon train exit exit exit
higher util new exist surgeon maci eas use benefit well
shorter rehabilit time could drive surgeon use even frequent
saw carticel current estim estim assum maci
procedur per surgeon project util drop maci procedur
per surgeon per quarter
unchang improv convers rate biopsi biopsi lead indic
maci sale growth acceler meaning last quarter
-- manag disclos
convers rate note held steadi maci roll-out
biopsi convert actual implant usual within month would impli revenu
growth first month could fall somewher rang vs
rang includ artifici inflat due easi y/i compar
favor gross margin profil variabl cog total
well-posit significantli expand gross margin ultim achiev sustain
oper incom net profit earlier beyond also market
autolog epiderm product address sever burn market
penetr believ epicel alon sustain high-single-digit low-double-digit grower
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi dcf
arriv valuat compar compani analysi arriv
valuat rang valuat appli ev/sal multipl
sale estim current share trade
estim sale estim repres discount
view compar higher-growth small-cap med-tech group current trade
sale estim sale estim believ fundament support
valuat ev/sal rang assum modest discount due vcel
concentr investor base gener lack awar regen medicin market
broadli specif
risk valuat includ inabl execut physician train drive ramp
maci adopt potenti product recalls/regulatori issu either maci epicel
competit entrant current unawar need rais addit capit
reach profit could dilut exist sharehold inabl optim
variabl cog control oper expens order drive posit leverag
